Aspirin-sensitive respiratory disease

Annual Review of Physiology

Volumn 71, Issue , 2009, Pages 465-487

  Farooque, Sophie P ^a   Lee, Tak H ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Asthma; COX 1 and COX 2 inhibitors; Cysteinyl leukotrienes; Nasal polyps; PGE2

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONATE 15 LIPOXYGENASE; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; PEPTIDOLEUKOTRIENE; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE; PROSTANOID RECEPTOR;

ASPIRIN SENSITIVE RESPIRATORY DISEASE; ASTHMA; CLINICAL FEATURE; DESENSITIZATION; DISEASE COURSE; DISEASE EXACERBATION; DRUG SENSITIVITY; HUMAN; ICOSANOID METABOLISM; NOSE POLYP; PATHOGENESIS; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; RESPIRATORY TRACT INFLAMMATION; REVIEW; RHINOSINUSITIS;

ASPIRIN; CYCLOOXYGENASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG TOLERANCE; EICOSANOIDS; HUMANS; LUNG DISEASES;

EID: 67651184065     PISSN: 00664278     EISSN: 15451585     Source Type: Book Series    
DOI: 10.1146/annurev.physiol.010908.163114     Document Type: Review

References (150)

1. Vane JR, Botting RM. 2003. The mechanism of action of aspirin. Thromb. Res. 110:255-258
2. Rinsema TJ. 1999. One hundred years of aspirin. Med. Hist. 43:502-507
3. Widal MF, Abrami P, Lenmoyez J. 1922. Anaphylaxie et idiosyncrasie. Presse Med. 30:189-192
4. Samter M, Beers RF Jr. 1968. Intolerance to aspirin. Clinical studies and consideration of its pathogenesis. Ann. Int. Med. 68:975-983
5. Mascia K, Haselkorn T, Deniz YM, Miller DP, Bleecker ER, Borish L. TENOR Study Group. 2005. Aspirin sensitivity and severity of asthma: evidence for irreversible airway obstruction in patients with severe or difficult-to-treat asthma. J. Allergy Clin. Immunol. 116:970-975 (Pubitemid 41571774)
6. Koga T, Oshita Y, Kamimura T, Koga H, Aizawa H. 2006. Characterisation of patients with frequent exacerbation of asthma. Respir. Med. 100:273-278 (Pubitemid 43078979)
7. Berges-Gimeno MP, Simon RA, Stevenson DD. 2002. The natural history and clinical characteristics of aspirin-exacerbated respiratory disease. Ann. Allergy Asthma Immunol. 89:474-478
8. Szczeklik A, Nizankowska E, Duplaga M. 2000. Natural history of aspirin-induced asthma. AIANE Investigators. European Network on Aspirin-Induced Asthma. Eur. Respir. J. 16:432-436
9. Makowska JS, Grzegorczyk J, Bienkiewicz B, Wozniak M, Kowalski ML. 2008. Systemic responses after bronchial aspirin challenge in sensitive patients with asthma. J. Allergy Clin. Immunol. 121:348-354
10. Rehl RM, Balla AA, Cabay RJ, Hearp ML, Pytynia KB, Joe SA. 2007. Mucosal remodeling in chronic rhinosinusitis. Am. J. Rhinol. 21:651-657
11. Kim JE, Kountakis SE. 2007. The prevalence of Samter's triad in patients undergoing functional endoscopic sinus surgery. Ear Nose Throat J. 86:396-399 (Pubitemid 351954491)
12. Kowalski ML, Lewandowska-Polak A, Woźniak J, Ptasińska A, Jankowski A, et al. 2005. Association of stem cell factor expression in nasal polyp epithelial cells with aspirin sensitivity and asthma. Allergy 60:631-637 (Pubitemid 40562469)
13. Awad OG, Fasano MB, Lee JH, Graham SM. 2008. Asthma outcomes after endoscopic sinus surgery in aspirin-tolerant versus aspirin-induced asthmatic patients. Am. J. Rhinol. 22:197-203
14. Kasper L, Sladek K, Duplaga M, Bochenek G, Liebhart L, Gladysz U. 2003. Prevalence of asthma with aspirin hypersensitivity in the adult population of Poland. Allergy 58:1064-1066 (Pubitemid 37260352)
15. Vally H, Taylor M, Thompson PJ. 2002. The prevalence of aspirin-intolerant asthma in Australian asthmatic patients. Thorax 57:569-574 (Pubitemid 34761756)
16. Settipane G, Chafee F, Klein D. 1974. Aspirin intolerance. II. A prospective study in an atopic and normal population. J. Allergy Clin. Immunol. 53:200-204
17. McDonald J, Mathison DA, Stevenson DD. 1972. Aspirin intolerance in asthma-detection by challenge. J. Allergy Clin. Immunol. 50:198-207
18. Settipane GA, Chafee FH. 1977. Nasal polyps in asthma and rhinitis. A review of 6,037 patients. J. Allergy Clin. Immunol. 59:17-21
19. Yoshimine F, Hasegawa T, Suzuki E, Terada M, Koya T, et al. 2005. Contribution of aspirin-intolerant asthma to near fatal asthma based on a questionnaire survey in Niigata Prefecture, Japan. Respirology 10:477-484 (Pubitemid 43942617)
20. Plaza V, Serrano J, Picado C, Sanchis J. High Risk Asthma Research Group. 2002. Frequency and clinical characteristics of rapid-onset fatal and near-fatal asthma. Eur. Respir. J. 19:846-852 (Pubitemid 34567897)
21. Picado C, Montserrat JM, Roca J, Rodríguez-Roisín R, Estopá R, et al. 1983. Mechanical ventilation in severe exacerbation of asthma. Study of 26 cases with six deaths. Eur. J. Respir. Dis. 64:102-107 (Pubitemid 13181055)
22. Bellomo R, McLaughlin P, Tai E, Parkin G. 1994. Asthma requiring mechanical ventilation. A low morbidity approach. Chest 105:891-896 (Pubitemid 24088478)
23. Szczeklik A, Gryglewski RJ, Czerniawska-Mysik G. 1975. Relationship of inhibition of prostaglandin biosynthesis by analgesics to asthma attacks in aspirin-sensitive patients. Br. Med. J. 1:67-69
24. DeWitt DL, el-Harith EA, Kraemer SA, Andrews MJ, Yao EF, et al. 1990. The aspirin and heme-binding sites of ovine and murine prostaglandin endoperoxide synthases. J. Biol. Chem. 265:5192-5198
25. Chiang N, Bermudez EA, Ridker PM, Hurwitz S, Serhan CN. 2004. Aspirin triggers antiinflammatory 15-epi-lipoxin A4 and inhibits thromboxane in a randomized human trial. Proc. Natl. Acad. Sci. USA 101:15178-15183 (Pubitemid 39391738)
26. Makowska JS, Grzegorczyk J, Bienkiewicz B, Wozniak M, Kowalski ML. 2008. Systemic responses after bronchial aspirin challenge in sensitive patients with asthma. J. Allergy Clin. Immunol. 121:348-354
27. Gamboa P, Sanz ML, Caballero MR, Urrutia I, Antépara I, et al. 2004. The flow-cytometric determination of basophil activation induced by aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) is useful for in vitro diagnosis of the NSAID hypersensitivity syndrome. Clin. Exp. Allergy 34:1448-1457 (Pubitemid 39233702)
28. Kowalski ML, Ptasinska A, Jedrzejczak M, Bienkiewicz B, Cieslak M, et al. 2005. Aspirin-triggered 15- HETE generation in peripheral blood leukocytes is a specific and sensitive Aspirin-Sensitive Patients Identification Test (ASPITest). Allergy 60:1139-1145 (Pubitemid 41153140)
29. Folco G, Murphy RC. 2006. Eicosanoid transcellular biosynthesis: from cell-cell interactions to in vivo tissue responses. Pharmacol. Rev. 58:375-388 (Pubitemid 44394907)
30. Higashi N, Taniguchi M, Mita H, Kawagishi Y, Ishii T, et al. 2004. Clinical features of asthmatic patients with increased urinary leukotriene E4 excretion (hyperleukotrienuria): involvement of chronic hyperplastic rhinosinusitis with nasal polyposis. J. Allergy Clin. Immunol. 113:277-283 (Pubitemid 38210550)
31. Antczak A, Montuschi P, Kharitonov S, Gorski P, Barnes PJ. 2002. Increased exhaled cysteinyl-leukotrienes and 8-isoprostane in aspirin-induced asthma. Am. J. Respir. Crit. Care Med. 166:301-306 (Pubitemid 34864417)
32. Szczeklik A, Sladek K, Dworski R, Nizankowska E, Soja J, et al. 1996. Bronchial aspirin challenge causes specific eicosanoid response in aspirin-sensitive asthmatics. Am. J. Respir. Crit. Care Med. 154:1608-1614 (Pubitemid 26424923)
33. Fischer AR, Rosenberg MA, Lilly CM, Callery JC, Rubin P, et al. 1994. Direct evidence for a role of the mast cell in the nasal response to aspirin in aspirin-sensitive asthma. J. Allergy Clin. Immunol. 94:1046-1056 (Pubitemid 124006619)
34. Sousa A, Pfister R, Christie PE, Lane SJ, Nasser SM, et al. 1997. Enhanced expression of cyclo-oxygenase isoenzyme 2 (COX-2) in asthmatic airways and its cellular distribution in aspirin-sensitive asthma. Thorax 52:940-945 (Pubitemid 27514487)
35. Varga EM, Jacobson MR, Masuyama K, Rak S, Till SJ, et al. 1999. Inflammatory cell populations and cytokine mRNA expression in the nasal mucosa in aspirin-sensitive rhinitis. Eur. Respir. J. 14:610-615 (Pubitemid 29479727)
36. Peters-Golden M, Henderson WR Jr. 2007. Leukotrienes. N. Engl. J. Med. 357:1841-1854
37. Sousa AR, Parikh A, Scadding G, Corrigan CJ, Lee TH. 2002. Leukotriene-receptor expression on nasal mucosal inflammatory cells in aspirin-sensitive rhinosinusitis. N. Engl. J. Med. 347:1493-1499 (Pubitemid 35257588)
38. Ying S, Meng Q, Scadding G, Parikh A, Corrigan CJ, Lee TH. 2006. Aspirin-sensitive rhinosinusitis is associated with reduced E-prostanoid 2 receptor expression on nasal mucosal inflammatory cells. J. Allergy Clin. Immunol. 117:312-318 (Pubitemid 43190145)
39. Celik G, Bavbek S, Misirligil Z, Melli M. 2001. Release of cysteinyl leukotrienes with aspirin stimulation and the effect of PGE2 on this release from peripheral blood leucocytes in aspirin-induced asthmatic patients. Clin. Exp. Allergy 31:1615-1622
40. Sestini P, Armetti L, Gambaro G, Pieroni MG, Refini RM, et al. 1996. Inhaled PGE2 prevents aspirininduced bronchoconstriction and urinary LTE4 excretion in aspirin-sensitive asthma. Am. J. Respir. Crit. Care Med. 153:572-575 (Pubitemid 26051332)
41. Sanak M, Levy BD, Clish CB, Chiang N, Gronert K, et al. 2000. Aspirin-tolerant asthmatics generate more lipoxins than aspirin-intolerant asthmatics. Eur. Respir. J. 16:44-49 (Pubitemid 30480126)
42. Kowalski ML, Ptasinska A, Bienkiewicz B, Pawliczak R, DuBuske L. 2003. Differential effects of aspirin and misoprostol on 15-hydroxyeicosatetraenoic acid generation by leukocytes from aspirin-sensitive asthmatic patients. J. Allergy Clin. Immunol. 112:505-512 (Pubitemid 37108553)
43. Pérez-Novo CA, Watelet JB, Claeys C, Van Cauwenberge P, Bachert C. 2005. Prostaglandin, leukotriene, and lipoxin balance in chronic rhinosinusitis with and without nasal polyposis. J. Allergy Clin. Immunol. 115:1189-1196 (Pubitemid 40824588)
44. Kowalski ML, Grzegorczyk J, Pawliczak R, Kornatowski T, Wagrowska-Danilewicz M, Danilewicz M. 2002. Decreased apoptosis and distinct profile of infiltrating cells in the nasal polyps of patients with aspirin hypersensitivity. Allergy 57:493-500
45. Bradding P, Walls AF, Holgate ST. 2006. The role of the mast cell in the pathophysiology of asthma. J. Allergy Clin. Immunol. 117:1277-1284 (Pubitemid 43795741)
46. Adamjee J, Suh YJ, Park HS, Choi JH, Penrose JF, et al. 2006. Expression of 5-lipoxygenase and cyclooxygenase pathway enzymes in nasal polyps of patients with aspirin-intolerant asthma. J. Pathol. 209:392-399 (Pubitemid 43997749)
47. Deleted in proof
48. Bischoff SC, Sellge G, Schwengberg S, Lorentz A, Manns MP. 1999. Stem cell factor-dependent survival, proliferation and enhanced releasability of purified mature mast cells isolated from human intestinal tissue. Int. Arch. Allergy Immunol. 118:104-107 (Pubitemid 29195479)
49. Undem BJ, Lichtenstein LM, Hubbard WC, Meeker S, Ellis JL. 1994. Recombinant stem cell factorinduced mast cell activation and smooth muscle contraction in human bronchi. Am. J. Respir. Cell Mol. Biol. 11:646-650
50. Nilsson G, Butterfield JH, Nilsson K, Siegbahn A. 1994. Stem cell factor is a chemotactic factor for human mast cells. J. Immunol. 15:3717-3723 (Pubitemid 24313877)
51. Dreschers S, Dumitru CA, Adams C, Gulbins E. 2007. The cold case: Are rhinoviruses perfectly adapted pathogens? Cell Mol. Life Sci. 64:181-191 (Pubitemid 46156886)
52. Cairns JA, Walls AF. 1996. Mast cell tryptase is a mitogen for epithelial cells: stimulation of IL-8 production and intercellular adhesion molecule-1 expression. J. Immunol. 156:275-283
53. Kupczyk M, Kupryś I, Danilewicz M, Bocheńska-Marciniak M, Murlewska A, et al. 2006. Adhesion molecules and their ligands in nasal polyps of aspirin-hypersensitive patients. Ann. Allergy Asthma Immunol. 96:105-111 (Pubitemid 43152676)
54. Wos M, Sanak M, Soja J, Olechnowicz H, Busse WW, Szczeklik A. 2008. The presence of rhinovirus in lower airways of patients with bronchial asthma. Am. J. Respir. Crit. Care Med. 177:1082-1089 (Pubitemid 351717566)
55. Wark PA, Johnston SL, Bucchieri F, Powell R, Puddicombe S, Laza-Stanca V. 2005. Asthmatic bronchial epithelial cells have a deficient innate immune response to infection with rhinovirus. J. Exp. Med. 201:937-947 (Pubitemid 40524463)
56. Szczeklik A. 1988. Aspirin-induced asthma as a viral disease. Clin. Allergy 18:15-20
57. Wang XS, Wu AY, Leung PS, Lau HY. 2007. PGE suppresses excessive anti-IgE induced cysteinyl leucotrienes production in mast cells of patients with aspirin exacerbated respiratory disease. Allergy 62:620-627
58. Bochenek G, Nagraba K, Nizankowska E, Szczeklik A. 2003. A controlled study of 9α,11β-PGF2 (a prostaglandin D2 metabolite) in plasma and urine of patients with bronchial asthma and healthy controls after aspirin challenge. J. Allergy Clin. Immunol. 111:743-749 (Pubitemid 36470243)
59. Nasser S, Christie PE, Pfister R, Sousa AR, Walls A, et al. 1996. Effect of endobronchial aspirin challenge on inflammatory cells in bronchial biopsy samples from aspirin-sensitive asthmatic subjects. Thorax 51:64-70 (Pubitemid 26047104)
60. Szczeklik A, Sladek K, Dworski R, Nizankowska E, Soja J, Sheller J. 1996. Bronchial aspirin challenge causes specific eicosanoid response in aspirin-sensitive asthmatics. Am. J. Respir. Crit. Care Med. 154:1608-1614 (Pubitemid 26424923)
61. Carpagnano GE, Resta O, Gelardi M, Spanevello A, Di Gioia G, et al. 2007. Exhaled inflammatory markers in aspirin-induced asthma syndrome. Am. J. Rhinol. 21:542-547 (Pubitemid 350099762)
62. Rosenberg HF, Phipps S, Foster PS. 2007. Eosinophil trafficking in allergy and asthma. J. Allergy Clin. Immunol. 119:1303-1310
63. Cowburn AS, Holgate ST, Sampson AP. 1999. IL-5 increases expression of 5-lipoxygenase-activating protein and translocates 5-lipoxygenase to the nucleus in human blood eosinophils. J. Immunol. 163:456-465
64. Sousa AR, Lams BE, Pfister R, Christie PE, Schmitz M, Lee TH. 1997. Expression of interleukin- 5 and granulocyte-macrophage colony-stimulating factor in aspirin-sensitive and nonaspirin-sensitive asthmatic airways. Am. J. Respir. Crit. Care Med. 156:1384-1389 (Pubitemid 27505498)
65. Mastalerz L, Sanak M, Szczeklik A. 2001. Serum interleukin-5 in aspirin-induced asthma. Clin. Exp. Allergy 31:1036-1040
66. Wills-Karp M. 2004. Interleukin-13 in asthma pathogenesis. Immunol. Rev. 202:175-190
67. Schmid-Grendelmeier P, Altznauer F, Fischer B, Bizer C, Straumann A, et al. 2002. Eosinophils express functional IL-13 in eosinophilic inflammatory diseases. J. Immunol. 169:1021-1027 (Pubitemid 34753462)
68. Espinosa K, Bossé Y, Stankova J, Rola-Pleszczynski M. 2003. CysLT1 receptor upregulation by TGF-β and IL-13 is associated with bronchial smooth muscle cell proliferation in response to LTD4. J. Allergy Clin. Immunol. 111:1032-1040 (Pubitemid 36570864)
69. Bossé Y, Thompson C, Audette K, Stankova J, Rola-Pleszczynski M. 2008. Interleukin-4 and interleukin- 13 enhance human bronchial smooth muscle cell proliferation. Int. Arch. Allergy Immunol. 146:138-148 (Pubitemid 351685477)
70. Saha SK, Berry MA, Parker D, Siddiqui S, Morgan A, et al. 2008. Increased sputum and bronchial biopsy IL-13 expression in severe asthma. J. Allergy Clin. Immunol. 121:685-691 (Pubitemid 351323866)
71. 2-related pathways by the Th2 cytokine IL-13. J. Allergy Clin. Immunol. 117:1446-1454
72. Borowski A, Kuepper M, Horn U, K.üpfer U, Zissel G, et al. 2008. Interleukin-13 acts as an apoptotic effector on lung epithelial cells and induces profibrotic gene expression in lung fibroblasts. Clin. Exp. Allergy 38:619-628
73. Holgate ST, Holloway J, Wilson S, Bucchieri F, Puddicombe S, Davies DE. 2004. Epithelialmesenchymal communication in the pathogenesis of chronic asthma. Proc. Am. Thorac. Soc. 1:93-98
74. 2 regulates wound closure in airway epithelium. Am. J. Physiol. Lung Cell Mol. Physiol. 280:L421-31
75. Dahlén SE, Hedqvist P, Hammarstrom S, Samuelsson B. 1980. Leukotrienes are potent constrictors of human bronchi. Nature 288:484-486 (Pubitemid 11163960)
76. Gyllfors P, Dahlén SE, Kumlin M, Larsson K, Dahlén B. 2006. Bronchial responsiveness to leukotriene D4 is resistant to inhaled fluticasone propionate. J. Allergy Clin. Immunol. 118:78-83 (Pubitemid 43964858)
77. Laitinen LA, Laitinen A, Haahtela T, Vilkka V, Spur BW, Lee TH. 1993. Leukotriene E4 and granulocytic infiltration into asthmatic airways. Lancet 341:989-990 (Pubitemid 23109169)
78. Christie PE, Tagari P, Ford-Hutchinson AW, Charlesson S, Chee P, Arm JA. 1991. Urinary leukotriene E4 concentrations increase after aspirin challenge in asthmatic subjects. Am. Rev. Respir. Dis. 102:5-29
79. Christie PE, Tagari P, Ford-Hutchinson AW, Black C, Markendorf A, et al. 1992. Urinary leukotriene E4 after lysine-aspirin inhalation in asthmatic subjects. Am. Rev. Respir. Dis. 146:1531-1534
80. Nasser SM, Patel M, Bell GS, Lee TH. 1995. The effect of aspirin desensitization on urinary leukotriene E4 concentrations in aspirin-sensitive asthma. Am. J. Respir. Crit. Care Med. 151:1326-1330
81. Picado C, Ramis I, Rosellò J, Prat J, Bulbena O, et al. 1992. Release of peptide leukotriene into nasal secretions after local instillation of aspirin in aspirin-sensitive asthmatic patients. Am. Rev. Respir. Dis. 145:65-69
82. Sanak M, Kielbasa B, Bochenek G, Szczeklik A. 2004. Exhaled eicosanoids following oral aspirin challenge in asthmatic patients. Clin. Exp. Allergy 34:1899-1904 (Pubitemid 40023641)
83. 4 synthase due to overactive transcription of an allelic variant associated with aspirin-intolerant asthma. Am. J. Respir. Cell Mol. Biol. 23:290-296
84. Cowburn AS, Sladek K, Soja J, Adamek L, Nizankowska E, Szczeklik A. 1998. Overexpression of leukotriene C4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma. J. Clin. Investig. 101:834-846 (Pubitemid 28096081)
85. Cai Y, Bjermer L, Halstensen TS. 2003. Bronchial mast cells are the dominating LTC4S-expressing cells in aspirin-tolerant asthma. Am. J. Respir. Cell Mol. Biol. 29:683-693 (Pubitemid 38045937)
86. Kawagishi Y, Mita H, Taniguchi M, Maruyama M, Oosaki R, et al. 2002. Leukotriene C4 synthase promoter polymorphism in Japanese patients with aspirin-induced asthma. J. Allergy Clin. Immunol. 109:936-942 (Pubitemid 34634302)
87. Sanak M, Simon HU, Szczeklik A. 1997. Leukotriene C4 synthase promoter polymorphism and risk of aspirin-induced asthma. Lancet 350:1599-1600 (Pubitemid 28036609)
88. Kedda MA, Shi J, Duffy D, Phelps S, Yang I, et al. 2004. Characterization of two polymorphisms in the leukotriene C4 synthase gene in an Australian population of subjects with mild, moderate, and severe asthma. J. Allergy Clin. Immunol. 113:889-895 (Pubitemid 38608598)
89. Van Sambeek R, Stevenson DD, Baldasaro M, Lam BK, Zhao J, et al. 2000. 5′ flanking region polymorphism of the gene encoding leukotriene C4 synthase does not correlate with the aspirin-intolerant asthma phenotype in the United States. J. Allergy Clin. Immunol. 106:72-76 (Pubitemid 30482855)
90. Kanaoka Y, Boyce Y. 2004. Cysteinyl leukotrienes and their receptors: cellular distribution and function in immune and inflammatory responses. J. Immunol. 173:1503-1510 (Pubitemid 38971578)
91. Lynch KR, O'Neill GP, Liu Q, Im DS, Sawyer N, et al. 1999. Characterization of the human cysteinyl leukotriene CysLT1 receptor. Nature 399:789-793 (Pubitemid 29293175)
92. Sarau HM, Ames RS, Chambers J, Ellis C, Elshourbagy N, et al. 1999. Identification, molecular cloning, expression, and characterization of a cysteinyl leukotriene receptor. Mol. Pharmacol. 56:657-663 (Pubitemid 29406893)
93. Heise CE, O'Dowd BF, Figueroa DJ, Sawyer N, Nguyen T, et al. 2000. Characterization of the human cysteinyl leukotriene 2 receptor. J. Biol. Chem. 275:30531-30536 (Pubitemid 30751375)
94. Nothacker HP, Wang Z, Zhu Y, Reinscheid RK, Lin SH, Civelli O. 2000. Molecular cloning and characterization of a second human cysteinyl leukotriene receptor: discovery of a subtype selective agonist. Mol. Pharmacol. 58:1601-1608
95. Chibana K, Ishii Y, Asakura T, Fukuda T. 2003. Up-regulation of cysteinyl leukotriene 1 receptor by IL-13 enables human lung fibroblasts to respond to leukotriene C4 and produce eotaxin. J. Immunol. 170:4290-4295 (Pubitemid 36428197)
96. Jiang Y, Borrelli LA, Kanaoka Y, Bacskai BJ, Boyce JA. 2007. CysLT2 receptors interact with CysLT1 receptors and down-modulate cysteinyl leukotriene dependent mitogenic responses of mast cells. Blood 110:3263-3270 (Pubitemid 350106319)
97. 2 in aspirin-sensitive and aspirin-tolerant chronic rhinosinusitis. J. Allergy Clin. Immunol. 115:316-322
98. Arm JP, O'Hickey SP, Spur BW, Lee TH. 1989. Airway responsiveness to histamine and leukotriene E4 in subjects with aspirin-induced asthma. Am. Rev. Respir. Dis. 140:148-153
99. Christie PE, Schmitz-Schumann M, Spur BW, Lee TH. 1993. Airway responsiveness to leukotriene C4 (LTC4), leukotriene E4 (LTE4) and histamine in aspirin-sensitive asthmatic subjects. Eur. Respir. J. 6:1468-1473
100. Lee TH, Austen KF, Corey EJ, Drazen JM. 1984. Leukotriene E4-induced airway hyperresponsiveness of guinea pig tracheal smooth muscle to histamine and evidence for three separate sulfidopeptide leukotriene receptors. Proc. Natl. Acad. Sci. USA 81:4922-4925
101. Pong SS, DeHaven RN. 1983. Characterization of a leukotriene D4 receptor in guinea pig lung. Proc. Natl. Acad. Sci. USA 80:7415-7419 (Pubitemid 14178013)
102. Bäck M, Norel X, Walch L, Gascard J, de Montpreville V, et al. 2000. Prostacyclin modulation of contractions of the human pulmonary artery by cysteinyl-leukotrienes. Eur. J. Pharmacol. 401:389-395 (Pubitemid 30608724)
103. Walch L, Norel X, Bäck M, Gascard JP, Dahlén SE, Brink C. 2002. Pharmacological evidence for a novel cysteinyl-leukotriene receptor subtype in human pulmonary artery smooth muscle. Br. J. Pharmacol. 137:1339-1345 (Pubitemid 36071752)
104. Krilis S, Lewis RA, Corey EJ, Austen KF. 1983. Specific receptors for leukotriene C4 on a smooth muscle cell line. J. Clin. Investig. 72:1516-1519
105. Pong SS, DeHaven RN, Kuehl FA Jr, Egan RW. 1983. Leukotriene C4 binding to rat lung membranes. J. Biol. Chem. 258:9616-9619
106. Drazen JM, Lewis RA, Austen KF, Corey EJ. 1983. Pulmonary phamacology of the SRS-A leukotrienes. In Leukotrienes and Prostacyclin, ed. F Berti, G Folco, GP Velo, pp. 125-134 New York: Plenum
107. Bandeira-Melo C, Woods LJ, Phoofolo M, Weller PF. 2002. Intracrine cysteinyl leukotriene receptor-mediated signaling of eosinophil vesicular transport-mediated interleukin-4 secretion. J. Exp. Med. 196:841-850
108. Arm JP, O'Hickey SP, Hawksworth RJ, Fong CY, Crea AE, et al. 1990. Asthmatic airways have a disproportionate hyperresponsiveness to LTE4, as compared with normal airways, but not to LTC4, LTD4, methacholine, and histamine. Am. Rev. Respir. Dis. 142:1112-1118
109. O'Hickey SP, Hawksworth RJ, Fong CY, Arm JP, Spur BW, Lee TH. 1991. Leukotrienes C4, D4, and E4 enhance histamine responsiveness in asthmatic airways. Am. Rev. Respir. Dis. 144:1053-1057
110. Arm JP, Austen KF. 2002. Leukotriene receptors and aspirin sensitivity. N. Engl. J. Med. 347:1524-1526
111. Yoshisue H, Kirkham-Brown J, Healy E, Holgate ST, Sampson AP, Davies DE. 2007. Cysteinyl leukotrienes synergize with growth factors to induce proliferation of human bronchial fibroblasts. J. Allergy Clin. Immunol. 119:132-140
112. Ciana P, Fumagalli M, Trincavelli ML, Verderio C, Rosa P, et al. 2006. The orphan receptor GPR17 identified as a new dual uracil nucleotides/cysteinyl- leukotrienes receptor. EMBO J. 25:4615-4627 (Pubitemid 44498134)
113. Pleskow WW, Stevenson DD, Mathison DA, Simon RA, Schatz M, Zeiger RS. 1982. Aspirin desensitization in aspirin-sensitive asthmatic patients: clinical manifestations and characterization of the refractory period. J. Allergy Clin. Immunol. 69:11-19
114. Stevenson DD. 2003. Aspirin desensitization in patients with AERD. Clin. Rev. Allergy Immunol. 24:159-168
115. Lee JY, Simon RA, Stevenson DD. 2007. Selection of aspirin dosages for aspirin desensitization treatment in patients with aspirin-exacerbated respiratory disease. J. Allergy Clin. Immunol. 119:157-164 (Pubitemid 46037806)
116. Jayawickreme SP, Gray T, Nettesheim P, Eling T. 1999. Regulation of 15-lipoxygenase expression and mucus secretion by IL-4 in human bronchial epithelial cells. Am. J. Physiol. 276:L596-603 (Pubitemid 29211361)
117. Nassar GM, Morrow JD, Roberts LJ 2nd, Lakkis FG, Badr KF. 1994. Induction of 15-lipoxygenase by interleukin-13 in human blood monocytes. J. Biol. Chem. 269:27631-27634
118. Bradding P, Redington AE, Djukanovic R, Conrad DJ, Holgate ST. 1995. 15-Lipoxygenase immunore-activity in normal and in asthmatic airways. Am. J. Respir. Crit. Care Med. 151:1201-1204
119. Peters-Golden M. 2002. 'Good' lipids for asthma. Nat. Med. 8:931-932
120. Serhan CN, Hamberg M, Samuelsson B. 1984. Lipoxins: novel series of biologically active compounds formed from arachidonic acid in human leukocytes. Proc. Natl. Acad. Sci. USA 81:5335-5339 (Pubitemid 14048742)
121. Stevenson DD, Szczeklik A. 2006. Clinical and pathologic perspectives on aspirin sensitivity and asthma. J. Allergy Clin. Immunol. 118:773-786 (Pubitemid 44515109)
122. Kowalski ML, Ptasinska A, Bienkiewicz B, Pawliczak R, DuBuske L. 2003. Differential effects of aspirin and misoprostol on 15 hydroxyeicosatetraenoic acid generation by leukocytes from aspirin-sensitive asthmatic patients. J. Allergy Clin. Immunol. 112:505-512 (Pubitemid 37108553)
123. Celik GE, Erkekol FO, Misirligil Z, Melli M. 2007. Lipoxin A4 levels in asthma: relation with disease severity and aspirin sensitivity. Clin. Exp. Allergy 37:1494-1501 (Pubitemid 47460233)
124. Feltenmark S, Gautam N, Brunnström A, Griffiths W, Backman L, et al. 2008. Eoxins are proinflammatory arachidonic acid metabolites produced via the 15-lipoxygenase-1 pathway in human eosinophils and mast cells. Proc. Natl. Acad. Sci. USA 105:680-685 (Pubitemid 351171768)
125. Vancheri C, Mastruzzo C, Sortino MA, Crimi N. 2004. The lung as a privileged site for the beneficial actions of PGE2. Trends Immunol. 25:40-46 (Pubitemid 38032806)
126. Holgate ST, Peters-Golden M, Panettieri RA, Henderson WR Jr. 2003. Roles of cysteinyl leukotrienes in airway inflammation, smooth muscle function, and remodeling. J. Allergy Clin. Immunol. 111:S18-34
127. Charbeneau RP, Peters-Golden M. 2005. Eicosanoids: mediators and therapeutic targets in fibrotic lung disease. Clin. Sci. (London) 108:479-491 (Pubitemid 40827555)
128. 2 inhibits fibroblast to myofibroblast transition via E prostanoid receptor 2 signaling and cyclic adenosine monophosphate elevation. Am. J. Respir. Cell Mol. Biol. 29:537-544
129. Szczeklik A, Mastalerz L, Nizankowska E, Cmiel A. 1996. Protective and bronchodilator effects of prostaglandin E and salbutamol in aspirin-induced asthma. Am. J. Respir. Crit. Care Med. 153:567-571 (Pubitemid 26051331)
130. Flamand N, Surette ME, Picard S, Bourgoin S. 2002. Cyclic AMP-mediated inhibition of 5-lipoxygenase translocation and leukotriene biosynthesis in human neutrophils. Mol. Pharmacol. 62:250-256 (Pubitemid 34804103)
131. Murakami M, Kudo I. 2006. Prostaglandin E synthase: a novel drug target for inflammation and cancer. Curr. Pharm. Des. 12:943-954
132. Bakhle YS. 1983. Synthesis and catabolism of cyclo-oxygenase products. Br. Med. Bull. 39:214-218
133. Kowalski ML, Pawliczak R, Wozniak J, Siuda K, Poniatowska M, et al. 2000. Differential metabolism of arachidonic acid in nasal polyp epithelial cells cultured from aspirin-sensitive and aspirin-tolerant patients. Am. J. Respir. Crit. Care Med. 161:391-398 (Pubitemid 30129443)
134. Pierzchalska M, Szabó Z, Sanak M, Soja J, Szczeklik A. 2003. Deficient prostaglandin E2 production by bronchial fibroblasts of asthmatic patients, with special reference to aspirin-induced asthma. J. Allergy Clin. Immunol. 111:1041-1048 (Pubitemid 36570865)
135. Ferreri NR, Howland WC, Stevenson DD, Spiegelberg HL. 1988. Release of leukotrienes, prostaglandins, and histamine into nasal secretions of aspirin-sensitive asthmatics during reaction to aspirin. Am. Rev. Respir. Dis. 137:847-854
136. Picado C, Ramis I, Rosellò J, Prat J, Bulbena O, Plaza V. 1992. Release of peptide leukotriene into nasal secretions after local instillation of aspirin in aspirin-sensitive asthmatic patients. Am. Rev. Respir. 145:65-69
137. Sanak M, Kielbasa B, Bochenek G, Szczeklik A. 2004. Exhaled eicosanoids following oral aspirin challenge in asthmatic patients. Clin. Exp. Allergy 34:1899-1904 (Pubitemid 40023641)
138. Sladek K, Dworski R, Soja J, Sheller JR, Nizankowska E, et al. 1994. Eicosanoids in bronchoalveolar lavage fluid of aspirin-intolerant patients with asthma after aspirin challenge. Am. J. Respir. Crit. Care Med. 149:940-946 (Pubitemid 24108486)
139. Narumiya S, Sugimoto Y, Ushikubi F. 1999. Prostanoid receptors: structures, properties, and functions. Physiol Rev. 79:1193-1226 (Pubitemid 29473315)
140. Jinnai N, Sakagami T, Sekigawa T, Kakihara M, Nakajima T, et al. 2004. Polymorphisms in the prostaglandin E2 receptor subtype 2 gene confer susceptibility to aspirin-intolerant asthma: a candidate gene approach. Hum. Mol. Genet. 13:3203-3217 (Pubitemid 40045272)
141. Parfenova H, Parfenov VN, Shlopov BV, Levine V, Falkos S, et al. 2001. Dynamics of nuclear localization sites for COX-2 in vascular endothelial cells. Am. J. Physiol. Cell Physiol. 281:C166-78 (Pubitemid 32927327)
142. Gyllfors P, Bochenek G, Overholt J, Drupka D, Kumlin M, et al. 2003. Biochemical and clinical evidence that aspirin-intolerant asthmatic subjects tolerate the cyclooxygenase 2-selective analgetic drug celecoxib. J. Allergy Clin. Immunol. 111:1116-1121 (Pubitemid 36570875)
143. Szczeklik A, Sanak M. 2006. The broken balance in aspirin hypersensitivity. Eur. J. Pharmacol. 533:145-155
144. Picado C, Fernandez-Morata JC, Juan M, Roca-Ferrer J, Fuentes M, Xaubet A. 1999. Cyclooxygenase-2 mRNA is downexpressed in nasal polyps from aspirin-sensitive asthmatics. Am. J. Respir. Crit. Care Med. 160:291-296 (Pubitemid 29326102)
145. Pujols L, Mullol J, Alobid I, Roca-Ferrer J, Xaubet A, Picado C. 2004. Dynamics of COX-2 in nasal mucosa and nasal polyps from aspirin-tolerant and aspirin-intolerant patients with asthma. J. Allergy Clin. Immunol. 114:814-819 (Pubitemid 39330251)
146. Sousa A, Pfister R, Christie PE, Lane SJ, Nasser SM, et al. 1997. Enhanced expression of cyclo-oxygenase isoenzyme 2 (COX-2) in asthmatic airways and its cellular distribution in aspirin-sensitive asthma. Thorax 52:940-945 (Pubitemid 27514487)
147. Mastalerz L, Sanak M, Gawlewicz-Mroczka A, Gielicz A, Cmiel A, Szczeklik A. 2008. Prostaglandin E2 systemic production in patients with asthma with and without aspirin hypersensitivity. Thorax 63:27-34
148. Szczeklik A, Stevenson DD. 2003. Aspirin-induced asthma: advances in pathogenesis, diagnosis, and management. J Allergy Clin. Immunol. 111:913-921 (Pubitemid 36570845)
149. Yoshida S, Sakamoto H, Yamawaki Y, Shoji T, Akahori K, et al. 1998. Effect of acyclovir on bronchoconstriction and urinary leukotriene E4 excretion in aspirin-induced asthma. J. Allergy Clin. Immunol. 102:909-914 (Pubitemid 29018305)
150. Pérez-Novo CA, Waeytens A, Claeys C, Cauwenberge PV, Bachert C. 2008. Staphylococcus aureus enterotoxin B regulates prostaglandin E2 synthesis, growth, and migration in nasal tissue fibroblasts. J. Infect. Dis. 197:1036-1043 (Pubitemid 351590033)